je.st
news
Tag: phase
DyStar to phase out Colour Index on eco-concerns
2015-04-08 14:13:00| Daily apparel & textile news and comment - from just-style.com
Textiles solution provider DyStar Group is to phase out use of the Colour Index because of its lack of consideration of environmental factors.
Tags: index
phase
colour
dystar
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Grazoprevir/Elbasvir, Mercks Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
2015-04-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Joe Romanelli, 908-740-1879Justin Holko, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
types
Auckland Transport awards first phase construction contracts for City Rail Link
2015-04-07 01:00:00| Railway Technology
New Zealand's Auckland Transport has appointed two contractors to carry out the first phase of the City Rail Link (CRL) construction in the downtown area.
Tags: link
city
construction
transport
Phase 1 Recommendations Draft
2015-04-06 19:04:12| PortlandOnline
PDF Document, 798kbCategory: Phase 1 Recommendations Pt.2 (April 2)
Tags: phase
recommendations
draft
Sites : [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] next »